Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 1-Methylimidazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | QPCT | Q16769 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Methylimidazole SCHEMBL4955404 | 1.00 | NFKB1 (0.71) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL27681653 | 1.00 | NFKB1 (0.71) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL27724089 | 0.98 | NFKB1 (0.68) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL27993647 | 0.98 | NFKB1 (0.68) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL28175971 | 0.96 | NFKB1 (0.65) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL28194536 | 0.93 | QPCT (0.68) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL459534 | 0.93 | QPCT (0.68) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL29777918 | 0.92 | NFKB1 (0.60) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL28122307 | 0.92 | NFKB1 (0.60) | NFKB1QPCTHSD17B10QPCTLHTT | |
| 1-Methylimidazole SCHEMBL29110568 | 0.91 | NFKB1 (0.65) | NFKB1QPCTHSD17B10QPCTLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705547-A1 | PROCESS FOR THE PREPARATION OF 1,1,4,4-TETRAALKYLOXY-2-BUTENE | DSM IP Assets B.V. (NL) | 2026-03-11 | — | — | EP | claimed |
| US-20250353823-A1 | PROCESS FOR THE PREPARATION OF ALKOXYLATED 2,5-DIHYDROFURAN | DSM IP ASSETS BV (NL) | 2025-11-20 | — | — | US | claimed |
| EP-4617650-A1 | FLEXIBLE ELECTROLYTE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Zhengzhou Winsen Electronics Technology Co., Ltd (CN) | 2025-09-17 | — | — | EP | claimed |
| EP-3275039-B1 | ELECTROLYTES AND METAL HYDRIDE BATTERIES | BASF CORP (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2025137231-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| CN-119978926-A | Luminous building paint and preparation method thereof | 庞双林 | 2025-05-13 | — | — | CN | claimed |
| EP-4540440-A1 | PROCESS FOR THE PREPARATION OF ALKOXYLATED 2,5-DIHYDROFURAN | DSM IP Assets B.V. (NL) | 2025-04-23 | — | — | EP | claimed |
| CN-119823109-A | An electrochromic material electrochromic composition and electrochromic device | 吉林大学 | 2025-04-15 | — | — | CN | claimed |
| CN-119797811-A | Water reducer composition and preparation method and application thereof | 浙江广天构件集团股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119530553-A | Treatment method of nickel cobalt hydroxide | 中冶瑞木新能源科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| WO-2008022983-A2 | CONDUCTIVE POLYMER GELS | BASF SE (DE) | 2008-02-28 | — | — | WO | claimed |
| US-20080044343-A1 | Process for the production of hydrogen peroxide | AKZO NOBEL N.V. (NL) | 2008-02-21 | — | — | US | claimed |
| WO-2008002255-A1 | PROCESS FOR THE PRODUCTION OF HYDROGEN PEROXIDE | AKZO NOBEL N.V. (NL) | 2008-01-03 | — | — | WO | claimed |
| EP-1789160-A1 | METHOD FOR SEPARATING HYDROGEN CHLORIDE AND PHOSGENE | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-30 | — | — | EP | claimed |
| EP-1663921-B1 | METHOD FOR PRODUCING HALOALKANES FROM ALCOHOLS | BASF AG (DE) | 2007-05-02 | — | — | EP | claimed |
| US-20070055084-A1 | Method for producing haloalkanes from alcohols | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1849281-A | Method for producing haloalkanes from alcohols | BASF AG (DE) | 2006-10-18 | — | — | CN | claimed |
| US-20060069169-A1 | Use of ionic liquids as coordination ligands for organometallic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-03-30 | — | — | US | claimed |
| WO-2006033990-A2 | USE OF IONIC LIQUIDS AS COORDINATION LIGANDS FOR ORGANOMETALLIC CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2006029788-A1 | METHOD FOR SEPARATING HYDROGEN CHLORIDE AND PHOSGENE | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353823-A1 | PROCESS FOR THE PREPARATION OF ALKOXYLATED 2,5-DIHYDROFURAN | CYP4F2, CYP4F12, CYP2F1 | NFKB1 1038/4885QPCT 1191/4885HSD17B10 220/4885 |
| US-20070055084-A1 | Method for producing haloalkanes from alcohols | ADH1C, HDHD5, ADH5 | NFKB1 2976/4885QPCT 510/4885HSD17B10 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.